122 related articles for article (PubMed ID: 37981697)
1. SBRT vs. Y90: HCC Treatment Outcomes and Costs.
deBettencourt MF; Liu Y; Cotler SJ; Molvar CA; Abdelrahman T; Thomas TO
Am J Clin Oncol; 2024 Mar; 47(3):99-104. PubMed ID: 37981697
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
[TBL] [Abstract][Full Text] [Related]
5. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.
Ettorre GM; Levi Sandri GB; Laurenzi A; Colasanti M; Meniconi RL; Lionetti R; Santoro R; Lepiane P; Sciuto R; Pizzi G; Cianni R; Golfieri R; D'Offizi G; Pellicelli AM; Antonini M; Vennarecci G
World J Surg; 2017 Jan; 41(1):241-249. PubMed ID: 27495316
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
[TBL] [Abstract][Full Text] [Related]
9. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
10. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
Ali R; Riaz A; Gabr A; Abouchaleh N; Mora R; Al Asadi A; Caicedo JC; Abecassis M; Katariya N; Maddur H; Kulik L; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2195-2202. PubMed ID: 28812136
[TBL] [Abstract][Full Text] [Related]
12. Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
Wehrenberg-Klee E; Gandhi RT; Ganguli S
Tech Vasc Interv Radiol; 2019 Jun; 22(2):70-73. PubMed ID: 31079713
[TBL] [Abstract][Full Text] [Related]
13. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
Vouche M; Salem R; Lewandowski RJ; Miller FH
Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
[TBL] [Abstract][Full Text] [Related]
14. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
Xing M; Kokabi N; Camacho JC; Kim HS
BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 Radioembolization: Current Indications and Outcomes.
Hamad A; Aziz H; Kamel IR; Diaz DA; Pawlik TM
J Gastrointest Surg; 2023 Mar; 27(3):604-614. PubMed ID: 36547759
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
17. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
[TBL] [Abstract][Full Text] [Related]
18. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.
Su TS; Liu QH; Zhu XF; Liang P; Liang SX; Lai L; Zhou Y; Huang Y; Cheng T; Li LQ
Radiat Oncol; 2021 Apr; 16(1):79. PubMed ID: 33882972
[TBL] [Abstract][Full Text] [Related]
19. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
